Baloxavir

Standard dose

Renal impairment

• No dose adjustment required.

Hepatic impairment

• Mild or moderate hepatic impairment (Child-Pugh class A or B): No dose adjustment is required.
• Severe hepatic impairment (Child-Pugh class C): Safety and efficacy have not been established in this patient group.

• Baloxavir marboxil should not be taken at the same time as products that contain polyvalent cations such as laxatives, antacids or oral supplements containing iron, zinc, selenium, calcium or magnesium. Use together may decrease plasma concentrations of baloxavir.
• Influenza vaccine (live): Baloxavir marboxil might decrease the efficacy of the live Influenza vaccine. Manufacturer advises separating administration.

This is not a complete list. Please see the BNF, Summary of Product Characteristics or speak to a pharmacist.

See BNF for up-to-date information

1. UK Health Security Agency (2025. Updated 23/1/26). Guidance on use of antiviral agents for the treatment and prophylaxis of seasonal influenza. [online] Available at: https://www.gov.uk/government/publications/influenza-treatment-and-prophylaxis-using-anti-viral-agents/guidance-on-use-of-antiviral-agents-for-the-treatment-and-prophylaxis-of-seasonal-influenza. [Accessed 31 Jan 2026]
2. BNF. (n.d.). Baloxavir marboxil. [online] Available at: https://bnf.nice.org.uk/drugs/baloxavir-marboxil/ [Accessed 31 Jan 2026].
3. Roche Products Limited. Summary of Product Characteristics. Xofluza 40 mg film coated tablets [online]. Last revision of the text 29/12/25. Available at: https://www.medicines.org.uk/emc/product/14764/smpc#gref [Accessed 31 Jan 2026].